Anavex Life Sciences (AVXL) Competitors

Anavex Life Sciences logo
$0.74 -0.08 (-9.49%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.81 +0.07 (+8.92%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AVXL vs. MDXG, EPRX, INDP, PRTA, and AVTE

Should you buy Anavex Life Sciences stock or one of its competitors? Anavex Life Sciences's main competitors and comparable companies include MiMedx Group (MDXG), Eupraxia Pharmaceuticals (EPRX), Indaptus Therapeutics (INDP), Prothena (PRTA), and Aerovate Therapeutics (AVTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anavex Life Sciences compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

MiMedx Group has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 2.5% of MiMedx Group shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MiMedx Group has higher revenue and earnings than Anavex Life Sciences. MiMedx Group is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiMedx Group$418.63M1.11$48.58M-$0.13N/A
Anavex Life SciencesN/AN/A-$46.38M-$0.15N/A

Anavex Life Sciences has a net margin of 0.00% compared to MiMedx Group's net margin of -6.32%. MiMedx Group's return on equity of 2.39% beat Anavex Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
MiMedx Group-6.32% 2.39% 1.85%
Anavex Life Sciences N/A -11.43%-10.72%

MiMedx Group currently has a consensus target price of $8.14, indicating a potential upside of 156.06%. Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 2,782.88%. Given Anavex Life Sciences' higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than MiMedx Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Anavex Life Sciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Anavex Life Sciences had 8 more articles in the media than MiMedx Group. MarketBeat recorded 11 mentions for Anavex Life Sciences and 3 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.86 beat Anavex Life Sciences' score of 0.06 indicating that MiMedx Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiMedx Group
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Anavex Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

MiMedx Group beats Anavex Life Sciences on 9 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, Eupraxia Pharmaceuticals had 7 more articles in the media than Anavex Life Sciences. MarketBeat recorded 18 mentions for Eupraxia Pharmaceuticals and 11 mentions for Anavex Life Sciences. Eupraxia Pharmaceuticals' average media sentiment score of 0.44 beat Anavex Life Sciences' score of 0.06 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eupraxia Pharmaceuticals
2 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Anavex Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Eupraxia Pharmaceuticals presently has a consensus price target of $18.00, indicating a potential upside of 171.90%. Anavex Life Sciences has a consensus price target of $21.33, indicating a potential upside of 2,782.88%. Given Anavex Life Sciences' higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Eupraxia Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eupraxia Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80
Anavex Life Sciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eupraxia PharmaceuticalsN/AN/A-$38.58M-$1.06N/A
Anavex Life SciencesN/AN/A-$46.38M-$0.15N/A

31.6% of Anavex Life Sciences shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Anavex Life Sciences' return on equity of -11.43% beat Eupraxia Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eupraxia PharmaceuticalsN/A -67.78% -46.73%
Anavex Life Sciences N/A -11.43%-10.72%

Eupraxia Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Summary

Anavex Life Sciences beats Eupraxia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Indaptus Therapeutics?

Anavex Life Sciences (NASDAQ:AVXL) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Anavex Life Sciences' return on equity of -11.43% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Anavex Life SciencesN/A -11.43% -10.72%
Indaptus Therapeutics N/A -206.91%-98.72%

In the previous week, Anavex Life Sciences had 8 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 11 mentions for Anavex Life Sciences and 3 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.70 beat Anavex Life Sciences' score of 0.06 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anavex Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Indaptus Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Anavex Life Sciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anavex Life SciencesN/AN/A-$46.38M-$0.15N/A
Indaptus TherapeuticsN/AN/A-$20.85M-$3.36N/A

Anavex Life Sciences currently has a consensus price target of $21.33, indicating a potential upside of 2,782.88%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Anavex Life Sciences is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Anavex Life Sciences beats Indaptus Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Anavex Life Sciences compare to Prothena?

Anavex Life Sciences (NASDAQ:AVXL) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Anavex Life Sciences has a net margin of 0.00% compared to Prothena's net margin of -45.44%. Prothena's return on equity of -9.98% beat Anavex Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Anavex Life SciencesN/A -11.43% -10.72%
Prothena -45.44%-9.98%-9.08%

In the previous week, Anavex Life Sciences had 9 more articles in the media than Prothena. MarketBeat recorded 11 mentions for Anavex Life Sciences and 2 mentions for Prothena. Prothena's average media sentiment score of 0.70 beat Anavex Life Sciences' score of 0.06 indicating that Prothena is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anavex Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prothena
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Anavex Life Sciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Prothena has a beta of -0.2, indicating that its share price is 120% less volatile than the broader market.

Anavex Life Sciences presently has a consensus price target of $21.33, suggesting a potential upside of 2,782.88%. Prothena has a consensus price target of $20.00, suggesting a potential upside of 142.13%. Given Anavex Life Sciences' higher probable upside, equities research analysts clearly believe Anavex Life Sciences is more favorable than Prothena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Prothena
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
2.86

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by insiders. Comparatively, 10.4% of Prothena shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Anavex Life Sciences has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anavex Life SciencesN/AN/A-$46.38M-$0.15N/A
Prothena$9.68M43.82-$244.09M-$0.48N/A

Summary

Anavex Life Sciences beats Prothena on 8 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

31.6% of Anavex Life Sciences shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Anavex Life Sciences has a consensus target price of $21.33, suggesting a potential upside of 2,782.88%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Anavex Life Sciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Anavex Life Sciences' return on equity of -11.43% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
Anavex Life Sciences N/A -11.43%-10.72%

In the previous week, Anavex Life Sciences had 11 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 11 mentions for Anavex Life Sciences and 0 mentions for Aerovate Therapeutics. Anavex Life Sciences' average media sentiment score of 0.06 beat Aerovate Therapeutics' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Aerovate Therapeutics Neutral
Anavex Life Sciences Neutral

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
Anavex Life SciencesN/AN/A-$46.38M-$0.15N/A

Summary

Anavex Life Sciences beats Aerovate Therapeutics on 12 of the 13 factors compared between the two stocks.

Get Anavex Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVXL vs. The Competition

MetricAnavex Life SciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$75.79M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-4.9326.6634.2628.24
Price / SalesN/A15.788.485.70
Price / CashN/A22.9521.0121.90
Price / Book0.674.184.463.72
Net Income-$46.38M-$24.15M$3.52B$393.10M
7 Day Performance-30.19%-7.78%-5.92%-5.76%
1 Month Performance-43.51%-5.96%-4.58%-7.14%
1 Year Performance-78.86%-8.08%-1.93%-7.46%

Anavex Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVXL
Anavex Life Sciences
2.0786 of 5 stars
$0.74
-9.5%
$21.33
+2,782.9%
-79.3%$75.79MN/AN/A34
MDXG
MiMedx Group
2.572 of 5 stars
$3.32
+0.3%
$8.14
+145.3%
-55.2%$466.96M$418.63MN/A808
EPRX
Eupraxia Pharmaceuticals
2.529 of 5 stars
$7.42
+7.7%
$17.17
+131.4%
+0.3%$454.55MN/AN/A49
INDP
Indaptus Therapeutics
0.611 of 5 stars
$3.13
-5.7%
N/A+46.3%$439.70MN/AN/A5
PRTA
Prothena
2.8894 of 5 stars
$8.77
+10.0%
$20.00
+128.1%
-19.4%$439.24M$9.68MN/A67

Related Companies and Tools


This page (NASDAQ:AVXL) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners